Ambulatory clinical pharmacy specialty services: The Kaiser permanente Colorado experience

Journal of Managed Care Pharmacy

Volumn 20, Issue 3, 2014, Pages 245-253

  Hill, Robin R ^a   Herner, Sheryl J ^b   Delate, Thomas ^c   Lyman Jr , Alfred E ^c  

^a Palliative Care   (United States)

^b Medication Safety   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; ARIPIPRAZOLE; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIAZEPAM; DICHLORALPHENAZONE PLUS ISOMETHEPTENE MUCATE PLUS PARACETAMOL; HEPATITIS A VACCINE; INFLUENZA VACCINE; INSULIN; LONG ACTING BETA AGONIST; MEVINOLIN; NEUROLEPTIC AGENT; PAMIDRONIC ACID; PIOGLITAZONE; PSYCHOTROPIC AGENT; RIFAXIMIN; RISPERIDONE; SEVELAMER; SHORT ACTING BETA AGONIST; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGY; ANTICOAGULANT THERAPY; ASTHMA; BARIATRIC SURGERY; BEHAVIORAL HEALTH; CANCER CHEMOTHERAPY; CARDIOLOGY; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CLINICAL PHARMACY; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIABETES MELLITUS; DRUG ELUTING STENT; ECONOMIC DEVELOPMENT; EMERGENCY WARD; ENDOCRINOLOGY; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; GENERAL PRACTITIONER; HEALTH; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH SERVICE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION; INFLUENZA VACCINATION; MEDICAL SPECIALIST; MEDICATION ERROR; MEDICATION THERAPY MANAGEMENT; MIGRAINE; MONOTHERAPY; NEPHROLOGY; NEUROLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ONCOLOGY; OUTPATIENT DEPARTMENT; PALLIATIVE THERAPY; PATIENT CARE; PATIENT EDUCATION; PATIENT SAFETY; PHARMACIST; PHYSICIAN; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROFESSIONAL PRACTICE; RESIDENCY EDUCATION; TENSION HEADACHE; UNITED STATES; WEIGHT REDUCTION;

AMBULATORY CARE; COLORADO; DELIVERY OF HEALTH CARE; HUMANS; PHARMACY SERVICE, HOSPITAL;

EID: 84896262740     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.3.245     Document Type: Note

References (63)

1. National Center for Health Statistics. Health, United States, 2011: with special feature on socioeconomic status and health. Hyattsville, MD. 2012. Tables 96 and 102. Available at: www.cdc.gov/nchs/data/hus/hus11.pdf#083. Accessed January 23, 2014.
2. Gurwich EL, Swanson LN. Clinical pharmacy practice in outpatient clinic. J Am Pharm Assoc. 1975;15(7):392-99.
3. Paulson PT, Bauch R, Paulson ML, Zilz DA. Medication data sheets: an aid to patient education. Drug Intell Clin Pharm. 1976;10(8):448-53.
4. Gabriel M, Gagnon JP, Bryan CK. Improved patient compliance through use of a daily drug reminder chart. Am J Public Health. 1977;67(10):968-69.
5. Sczupak CA, Conrad WF. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm. 1977;34(11):1238-42.
6. Ludy JA, Gagnon JP, Caiola SM. The patient-pharmacist interaction in two ambulatory settings: its relationship to patient satisfaction and drug misuse. Drug Intell Clin Pharm. 1977;11(2):81-89.
7. Schilling KW. Pharmacy program for monitoring diabetic patients. Am J Hosp Pharm. 1977;34(11):1242-45.
8. Brown DJ, Helling DK, Jones ME. Evaluation of clinical pharmacist consultations in a family practice office. Am J Hosp Pharm. 1979;36(7):912-15.
9. Davis S. Evaluation of pharmacist management of streptococcal throat infections in a health maintenance organization. Am J Hosp Pharm. 1978;35(5):561-66.
10. Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother. 1999;33(12):1336-55.
11. Tully MP, Seston EM. Impact of pharmacists providing a prescription review and monitoring service in ambulatory care or community practice. Ann Pharmacother. 2000;34(11):1320-31.
12. Nkansah N, Mostovetsky O, Yu C, et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD000336.
13. Rosen CE, Holmes S. Pharmacist's impact on chronic psychiatric outpatients in community mental health. Am J Hosp Pharm. 1978;35(6):704-08.
14. Bond CA, Salinger RJ. Fluphenazine outpatient clinics: a pharmacist's role. J Clin Psychiatry. 1979;40(12):501-03.
15. Knapp KK, Okamoto MP, Black BL. ASHP survey of ambulatory care pharmacy practice in health systems-2004. Am J Health Syst Pharm. 2005;62(3):274-84.
16. Finley PR, Crismon ML, Rush AJ. Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy. 2003;23(12):1634-44.
17. Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy. 1996;16(4):708-14.
18. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421-36.
19. Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Skog J, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm. 2006;63(14):1325-31.
20. Zillich AJ, Saseen JJ, DeHart RM, et al. Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2005;25(1):123-43.
21. Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dial. 2002;15(1):45-49.
22. Ponniah A, Anderson B, Shakib S, Doecke CJ, Angley M. Pharmacists' role in the post-discharge management of patients with heart failure: a literature review. J Clin Pharm Ther. 2007;32(4):343-52.
23. Benavides S, Rodriguez JC, Maniscalco-Feichtl M. Pharmacist involvement in improving asthma outcomes in various healthcare settings: 1997 to present. Ann Pharmacother. 2009;43(1):85-97.
24. Skelton JB. White paper on expanding the role of pharmacists in caring for individuals with Alzheimer's disease: APhA Foundation Coordinating Council to Improve Collaboration in Supporting Patients with Alzheimer's Disease. J Am Pharm Assoc (2003). 2008;48(6):715-21.
25. Von Gunten V, Reymond JP, Beney J. Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review. Pharm World Sci. 2007;29(3):146-63.
26. Helling DK, Nelson KM, Ramirez JE, et al. Kaiser Permanente Colorado Region Pharmacy Department: innovative leader in pharmacy practice. J Am Pharm Assoc (2003). 2006;46(1):67-76.
27. Heilmann RM, Campbell SM, Kroner BA, et al. Evolution, current structure, and role of a primary care clinical pharmacy service in an integrated managed care organization. Ann Pharmacother. 2013;47(1):124-31.
28. National Committee for Quality Assurance. Health plan report cards. Available at: http://reportcard.ncqa.org/plan/external/About. aspx?Tab=MeasuresPerformance. Accessed January 27, 2014.
29. National Committee for Quality Assurance. HEDIS 2013. Available at: http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2013.aspx. Accessed January 17, 2014.
30. U.S. Department of Health and Human Services. Expert panel report 3: guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program. August 27, 2008. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed January 17, 2014.
31. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-42.
32. STAR D. Sequenced treatment alternatives to relieve depression. Available at: http://www.edc.gsph.pitt.edu/stard/. Accessed January 17, 2014.
33. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
34. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-22.
35. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-10.
36. U.S. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). August 24, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm. Accessed January 17, 2014.
37. Olson KL, Delate T, Dugan D. Monitoring of patients given second-generation antipsychotic agents. Psych Serv. 2006;57(7):1045-46
38. Johnson SG, Canty K, Billups S, Schimmer J. Adherence to amiodarone monitoring recommendations before and after implementation of a centralized pharmacy service: a cohort study. J Pharm Pract. 2010;23(6):536-39.
39. U.S. Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). Updated January 7, 2014. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm111350.htm. Accessed January 17, 2014.
40. Raebel MA, Charles J, Dugan J, et al. Randomized trial to improve prescribing safety in ambulatory elderly patients. J Am Geriatr Soc. 2007;55(7):977-85.
41. Vogel EA, Klockars SJ, Billups SJ, Dugan JP. Diazepam conversion in older adults. J Am Geriatr Soc. 2010;58(6):1204-05.
42. U.S. Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. June 15, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed January 17, 2014.
43. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-31.
44. Tran MT, Billups SJ. Can guideline adherence be improved by letter outreach? Diabetes Care. 2008;31(4):e22.
45. Tran MT, Delate T, Bachmann S. Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 diabetes mellitus. Pharmacy Practice. 2008;6(2):79-87.
46. Ghany MG, Nelson DR, Strader, DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
47. Bass NM, Mullen, KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81.
48. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology. 2011;140(4):1155-65.
49. Wall GC, Schirmer LL, Page MJ. Pharmacotherapy for microscopic colitis. Pharmacotherapy. 2007;27(3):425-33.
50. Jackson AB, Humphries TL, Nelson KM, Helling DK. Clinical pharmacy travel medicine services: a new frontier. Ann Pharmacother. 2004;38(12):2160-65.
51. Herner SJ, Paulson DC, Delate T, Witt DM, Vondracek TG. Evaluation of venous thromboembolism risk following hospitalization. J Thromb Thrombolysis. 2011;32(1):32-39.
52. Bayliss EA, Bhardwaja B, Ross C, et al. Multidisciplinary team care may slow the rate of decline in renal function. Clin J Am Soc Nephrol. 2011;6(4):704-10.
53. Bhardwaja B, Carroll NM, Raebel MA, et al. Improving prescribing safety in patients with renal insufficiency in the ambulatory setting: the Drug Renal Alert Pharmacy (DRAP) program. Pharmacotherapy. 2011;31(4):346-56.
54. Bhardwaja B, Carroll N, Korner E, et al. Impact of prescription benefit coverage limits on sevelamer hydrochloride adherence for patients with ESRD. American Health & Drug Benefits. 2009;2(6):242-50.
55. Kinikar SA, Delate T, Menaker-Wiener CM, Bentley WH. Clinical outcomes associated with brand-to-generic phenytoin interchange. Ann Pharmacother. 2012;46(5):650-58.
56. Delate T, Aiello Bowles E, Pardee R, et al. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012;21(4):673-80.
57. Ritzwoller DP, Carroll NM, Delate T, et al. Patterns and predictors of first-line chemotherapy use among adults with advanced-small cell lung cancer in the Cancer Research Network. Lung Cancer. 2012;78(3):245-52.
58. Hill, RR. Clinical pharmacy services in a home-based palliative care program. Am J Health Syst Pharm. 2007;64(8):806,808,810.
59. Hill RR, Martinez KD, Delate T, Witt DM. A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services. J Thromb Thrombolysis. 2009;27(3):334-39.
60. Flowers L, Wick J, Figg WD Sr, et al. U.S. Public Health Service Commissioned Corps pharmacists: making a difference in advancing the nation's health. J Am Pharm Assoc (2003). 2009;49(3):446-52.
61. Harris IM, Baker E, Berry TM, et al. Developing a business-practice model for pharmacy services in ambulatory settings. Pharmacotherapy. 2008;28(2):285.
62. Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures- 2012. Am J Health Syst Pharm. 2012;69(5):405-21.
63. Centers for Medicare & Medicaid Services. Accountable care organizations (ACO). March 22, 2013. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ACO/index.html?redirect=/aco. Accessed January 17, 2014.